We serve Chemical Name:N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]ethanamine CAS:915924-40-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]ethanamine](https://a.dearchem.com/CAS2/915924-40-2.png)
Chemical Name:N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]ethanamine
CAS.NO:915924-40-2
Synonyms:N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]ethanamine
Molecular Formula:C7H13N3O
Molecular Weight:155.19800
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:242.8ºC at 760 mmHg
Density:1.037g/cm3
Index of Refraction:1.474
PSA:50.95000
Exact Mass:155.10600
LogP:1.13240
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]ethanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]ethanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]ethanamine Use and application,N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]ethanamine technical grade,usp/ep/jp grade.
Related News: These have since been joined by many other types of enzyme, including transaminases, oxidases, nitrilases, aldolases, and ammonia lyases, all of which perform distinct functions. monochromium(III) monothiocyanate manufacturers The review considered two cases of AML in patients treated with an investigational medicine, bb1111, in a clinical trial for sickle cell disease. Although there have been no reports of AML with Zynteglo, both medicines use the same viral vector and there was a concern that the vector may be implicated in the development of the cancer (insertional oncogenesis). 5-bromo-8-hydroxy-1,6-naphthyridine-7-carbonitrile suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. Butan-1-ol vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. Butan-1-ol vendor & factory.
